PREDICTMEDIX AI INC - PMEDF STOCK NEWS

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a major upgrade to its Safe Entry Stations, a series of AI-powered health screening tools. The new technology will now include non-invasive blood pressure readings, enhancing the ability to detect cardiovascular diseases, the world's leading cause of death. Existing features include temperature, heart rate, respiratory rate, and oxygen saturation monitoring. The integration of Heart Rate Variability (HRV) analysis is also being introduced, providing early indicators of various diseases. Trials for blood oxygen saturation screening are set to commence in India. Dr. Rahul Kushwah, COO of Predictmedix, emphasized the importance of these developments in making healthcare more efficient and accessible. The company aims to partner with global leaders to establish AI-powered health screening as a standard in medical care.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced a purchase order from MGM Healthcare, one of India's largest government hospital groups, for five AI-powered Safe Entry Stations. This order, valued at approximately $500,000 CAD over three years, follows a successful clinical study involving 400 patients, validating the effectiveness of the technology. The Safe Entry Stations offer rapid, non-invasive health screenings, enhancing efficiency and patient care in healthcare settings. Dr. Rahul Kushwah emphasized the opportunity for expansion in South Asia and ASEAN countries, where the technology could significantly improve healthcare outcomes.

Predictmedix Inc. (CSE:PMED) has achieved recognition in a major Indonesian newspaper for its AI-powered Safe Entry Station. This technology, validated on over 2,000 individuals, screens key vital signs non-invasively to detect health risks. The University of Raharja is collaborating with the Indonesian government to advance Safe Entry as a medical device. Since the last update, an additional 400 individuals have been screened, reflecting the urgent need for health solutions in Indonesia's 2,500 hospitals. The company also granted 600,000 stock options with an exercise price of $0.15, highlighting its growth initiatives.

Predictmedix Inc. has announced an update on its AI-powered impairment detection technology following a US patent grant for non-invasive detection of impairment from alcohol and/or cannabis. The technology boasts over 90% accuracy using multispectral imaging and speech analysis, with expectations for improved performance due to AI advancements. Targeting global law enforcement and high-risk industries, Predictmedix aims to capitalize on the $39 billion workplace safety market and $22.24 billion drug screening market projected to grow significantly by 2031. The company is focusing on commercializing a mobile app alongside a multispectral imaging camera for impairment detection.

Predictmedix Inc. has received a US patent for its AI-powered technology designed for non-invasive detection of impairment caused by alcohol and cannabis. This innovative system employs multispectral imaging and speech analysis to assess individuals' physiological states rapidly, offering a contactless alternative to traditional tests. The technology is integrated into the Company’s Fit for Duty screening solutions and Safe Entry system, which analyze data in mere seconds. The global workplace safety market is projected to grow significantly, indicating strong market potential for Predictmedix's patented solutions, aimed at improving workplace safety and health assessment.